Dave Stack News Today

Bupivacaine liposome injectable suspension was shown to reduce opioid use after surgery and significantly improve pain.

— EXPAREL is the only FDA-approved single-dose regional analgesic to safely demonstrate four days of superiority versus bupivacaine in two clinical studies —  — New indications for use as an...

Net Income of $10.9 Million Despite Slight Decrease in Total Revenues

-- Enhances diversity and expertise in key areas including scientific, commercial, and financial -- TAMPA, Fla., Oct. 10, 2023 -- Pacira BioSciences, Inc. , the industry leader in its commitment...

Operator: Good day and thank you for standing by. Welcome to the Q2, 2023 Pacira BioSciences Inc. Earnings Conference Call. At this time, all participants are in listen-only mode.

-- Conference call today at 8:30 a.m. ET -- TAMPA, Fla., Aug. 02, 2023 -- Pacira BioSciences, Inc. , the industry leader in its commitment to non-opioid pain management and regenerative health...

The FDA has accepted sNDA for Exparel (bupivacaine liposome injectable suspension) to include sciatic nerve block and femoral nerve block.

TAMPA, Fla., March 29, 2023 -- Pacira BioSciences, Inc. , the industry leader in its commitment to non-opioid pain management and regenerative health solutions, today announced the U.S. Food and... | March 29, 2023

TAMPA, Fla., March 27, 2023 -- Pacira BioSciences, Inc. today announced that the United States Court of Appeals for the Third Circuit affirmed the District Court’s dismissal of the... | March 27, 2023

10.08.2022 - - EXPAREL average daily sales for July 2022 were 105 percent of July 2021 - TAMPA, Fla., Aug. 10, 2022 (GLOBE NEWSWIRE) - Pacira BioSciences, Inc. (Nasdaq: PCRX), the industry leader in its commitment to non-opioid pain management and ... Seite 1